Vision & Advantages
DESTINATION challenges the current mRNA/DNA delivery paradigm, which is broadly focused on 3 main strategies for mRNA delivery:
Viral approaches that suffer from immunogenicity issues, complex and high-cost manufacturing;
Non-viral vectors primarily lipids and polymers with main disadvantages related to poor selectivity/off-target effects and immunogenicity; and
Naked/unprotected delivery, which limits the use of mRNAs to indications amenable to local administration.
The disadvantages of these delivery systems limit the clinical and commercial potential of mRNA/DNA therapeutics. RNanos utilise a unique and disruptive strategy compared to competitors, designed to ensure the following competitive advantages: enhanced safety, efficacy, and scalable synthesis, manufacturing and production.